Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb IschemiaRutherford 5

Next Previous
Search
Trial Profile

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb IschemiaRutherford 5

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Chronic limb-threatening ischemia; Peripheral arterial disorders; Ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms HOPE CLTI-2; Rutherford 5
  • Sponsors Beijing Northland Biotech

    • Most Recent Events

    • 19 Jun 2024 Status changed from recruiting to completed.
    • 12 Aug 2022 Trial design and rationale from tow clinical trials (HOPE CLTI-1 and HOPE CLTI-2) published in the American Heart Journal
    • 29 Mar 2022 Planned End Date changed from 6 Mar 2022 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top